Scancell (LON:SCLP) Hits New 1-Year Low – Time to Sell?

Scancell Holdings plc (LON:SCLP)’s stock price reached a new 52-week low during mid-day trading on Wednesday. The stock traded as low as GBX 85.20 and last traded at GBX 85.20, with a volume of 321,031 shares traded. The stock had previously closed at GBX 86.40.

Scancell Trading Down 0.6%

The business has a 50 day simple moving average of GBX 94.71 and a two-hundred day simple moving average of GBX 132.60. The company has a current ratio of 0.28, a quick ratio of 13.01 and a debt-to-equity ratio of -88.01. The company has a market cap of £1.17 billion, a PE ratio of -156.18 and a beta of 0.69.

Scancell (LON:SCLP) last issued its earnings results on Friday, October 9th. The company reported GBX (17.30) EPS for the quarter. Scancell had a negative net margin of 116.98% and a positive return on equity of 128.87%. On average, analysts forecast that Scancell Holdings plc will post -2.54 EPS for the current fiscal year.

About Scancell

Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.